Recognition Health

Fairfax, Virginia 22031

7 studies enrolling now · 21 studies all time

What they study most

Alcohol Use Disorder, Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Amyloid, Bipolar Disorder, Brain Diseases, Central Nervous System Diseases, Cognitive Dysfunction, Dementia, Depressive Disorder, Major, Early Alzheimer's Disease

Studies at this site

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder — Recruiting now
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) — Recruiting now
• A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder — Recruiting now
• A Study of Brenipatide in Participants With Alcohol Use Disorder — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — Stopped early
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• Study of ASN51 in Adults With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease — Completed
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA) — Completed
• SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• Fasudil fOr redUcing elopemeNt and Spatial Disorientation — Completed